Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties.

Valentina AudritoEnrico MoisoFilippo UgoliniVincenzo Gianluca MessanaLorenzo BrandimarteIlaria ManfredoniaSimonetta BianchiFrancesco De LoguRomina NassiniAnna Szumera-CiećkiewiczDaniela TavernaDaniela MassiSilvia Deaglio

Published in: Journal of translational medicine (2022)

Overall, the association between BRAF mutations and NAMPT expression identifies a subset of tumors more sensitive to NAMPT inhibition opening the way for novel combination therapies including NAMPTi with BRAFi/MEKi, to postpone and/or overcome drug resistance. Lastly, the over-expression of NAMPT in several tumors could be a key and broad event in tumorigenesis, substantiated by the finding of NAMPT gene amplification.

Keyphrases

poor prognosis
genome wide
binding protein
transcription factor
copy number
long non coding rna
metastatic colorectal cancer
dna methylation
nucleic acid
genome wide identification